- Home
- TBI vs VTYX Comparison
TBI vs VTYX Comparison
Compare TBI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- VTYX
- Stock Information
- Founded
- TBI 1985
- VTYX 2018
- Country
- TBI United States
- VTYX United States
- Employees
- TBI N/A
- VTYX N/A
- Industry
- TBI Professional Services
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- TBI Consumer Discretionary
- VTYX Health Care
- Exchange
- TBI Nasdaq
- VTYX Nasdaq
- Market Cap
- TBI 169.0M
- VTYX 154.9M
- IPO Year
- TBI 1996
- VTYX 2021
- Fundamental
- Price
- TBI $5.80
- VTYX $2.05
- Analyst Decision
- TBI Buy
- VTYX Buy
- Analyst Count
- TBI 1
- VTYX 4
- Target Price
- TBI $10.00
- VTYX $11.33
- AVG Volume (30 Days)
- TBI 525.7K
- VTYX 1.5M
- Earning Date
- TBI 05-05-2025
- VTYX 05-08-2025
- Dividend Yield
- TBI N/A
- VTYX N/A
- EPS Growth
- TBI N/A
- VTYX N/A
- EPS
- TBI N/A
- VTYX N/A
- Revenue
- TBI $1,534,794,000.00
- VTYX N/A
- Revenue This Year
- TBI $0.80
- VTYX N/A
- Revenue Next Year
- TBI $6.90
- VTYX N/A
- P/E Ratio
- TBI N/A
- VTYX N/A
- Revenue Growth
- TBI N/A
- VTYX N/A
- 52 Week Low
- TBI $3.45
- VTYX $0.78
- 52 Week High
- TBI $12.29
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- TBI 61.64
- VTYX 62.71
- Support Level
- TBI $5.82
- VTYX $1.65
- Resistance Level
- TBI $6.28
- VTYX $1.85
- Average True Range (ATR)
- TBI 0.36
- VTYX 0.15
- MACD
- TBI 0.07
- VTYX 0.03
- Stochastic Oscillator
- TBI 70.33
- VTYX 69.32
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.